Article
NeurologyLive Friday 5 — January 17, 2020
Author(s):
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Elizabeth Gerard, MD: The MONEAD Study Findings
The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine discussed the rates of breastfeeding among women with epilepsy and ways to close the gap.
2: Will Gepants and Monoclonal Antibodies Be Used in Tandem for Migraine?
Findings from the first clinical report of a small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP used in tandem suggest that a combined treatment approach may be safe and effective in migraine. We spoke with study investigator Kathleen Mullin, MD, to learn more about what this means for the future of migraine treatment.
3: Advice to Community Neurologists Treating Parkinson Disease
Expert neurologists Jill M. Giordano Farmer, DO, MPH; Rajesh Pahwa, MD; Daniel E. Kremens, MD, JD; Peter LeWitt, MD, M.Med.Sc; and Stuart Isaacson, MD, consider the future treatments for Parkinson disease and provide community neurologists with management advice.
4: Ocrelizumab Drug Label Updated With New Safety Information
The FDA approved an updated drug label for the multiple sclerosis drug, including updates on immunizations and risks in specific patient populations.
5: Lamotrigine Recalled Due to Cross-Contamination
The recalled lot of lamotrigine used to treat epilepsy and bipolar disorder is set to expire in June 2021 and was distributed between August 23 and August 30, 2019.
